--- title: "Cosunter: Research results of the innovative drug GST-HG131 for hepatitis B treatment accepted as the latest breakthrough abstract report at the annual meeting of the American Association for the Study of Liver Diseases" type: "News" locale: "en" url: "https://longbridge.com/en/news/260625310.md" description: "Cosunter announced that the Phase II clinical research results of its innovative drug GST-HG131 have been accepted by the American Association for the Study of Liver Diseases (AASLD) as a breakthrough abstract report for the 2025 annual meeting. GST-HG131 is the world's first oral HBsAg inhibitor to complete Phase II clinical trials, demonstrating significant HBsAg suppression effects, with some patients showing sustained reductions in HBsAg levels after discontinuation of the drug. Due to its clinical advantages, the drug has been included in the list of breakthrough therapy designations by the National Medical Products Administration" datetime: "2025-10-10T11:54:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/260625310.md) - [en](https://longbridge.com/en/news/260625310.md) - [zh-HK](https://longbridge.com/zh-HK/news/260625310.md) --- # Cosunter: Research results of the innovative drug GST-HG131 for hepatitis B treatment accepted as the latest breakthrough abstract report at the annual meeting of the American Association for the Study of Liver Diseases According to the Zhitong Finance APP, Cosunter (300436.SZ) announced that its innovative drug holding subsidiary, Fujian Guangsheng Zhonglin Biotechnology Co., Ltd., recently received notification from the American Association for the Study of Liver Diseases (AASLD), a leading professional academic institution in the global liver disease research field. The complete results of the Phase II clinical study of the innovative drug GST-HG131 for hepatitis B treatment have been officially accepted as a Late Breaking Abstract Parallel Presentation at The Liver Meeting® 2025, marking a significant recognition of the clinical research results of the company's innovative hepatitis B drug GST-HG131 by the international academic community. GST-HG131 is currently the world's first oral HBsAg inhibitor to complete Phase II clinical trials, demonstrating good accessibility and patient compliance. The Phase II clinical trial showed that, despite the generally low baseline HBsAg levels in the trial patients, HBsAg still decreased rapidly, with the fastest patient showing a reduction of approximately 0.8Log10 IU/mL within 7 days. In the third group (30mg, BID, three-month administration group), the average reduction reached 12.88%, a decrease of 87.12%; the highest reduction reached 2.29%, a decrease of 97.71%. In the third group study, 76.5% of patients achieved HBsAg levels ≤100 IU/mL (sustained HBsAg ≤100 IU/mL after stopping treatment is an important indicator of partial cure), and the HBsAg levels of patients continued to decline, with a rapid downward trend still observed at the time of stopping treatment. The rebound of HBsAg after stopping treatment was significantly lower than the original baseline. If the administration time is extended or combined treatment is applied, better efficacy is expected. In July 2025, GST-HG131 was included in the list of breakthrough therapies by the National Medical Products Administration due to existing data indicating significant clinical advantages. GST-HG131 has a significant inhibitory effect on HBsAg, while GST-HG141 further significantly inhibits HBV DNA on the basis of nucleoside drug treatment and has potential effective inhibition and depletion effects on HBV cccDNA, thereby preventing viral rebound. The two are expected to have synergistic and complementary effects in antiviral mechanisms. Based on nucleos(t) ide analog (NUC) basic treatment, the Phase II clinical trial project of GST-HG131 combined with GST-HG141 for hepatitis B treated patients is expected to challenge clinical cure for hepatitis B and is a key innovative drug with significant clinical value supported by the national policy system for the development of innovative drugs throughout the entire chain. The combined treatment plan has been included in the national "Optimization of Innovative Drug Clinical Trial Review and Approval Pilot Project" and has obtained clinical trial application approval ### Related Stocks - [300436.CN](https://longbridge.com/en/quote/300436.CN.md) ## Related News & Research - [Global Inflation Fears Are Driving Bond Yields Higher. Make This 1 Trade Now.](https://longbridge.com/en/news/286932294.md) - [$2.4M earned by Polymarket wallets with 98% accuracy on military bets sparks insider trading fears.](https://longbridge.com/en/news/286990280.md) - [15:37 ETMuse Communications Celebrates 10 Years of Award-Winning Legal Marketing and Public Relations](https://longbridge.com/en/news/286811115.md) - [Suning.Com Puts Insolvent Carrefour China Business up for Sale at CNY1 Starting Price](https://longbridge.com/en/news/286893780.md) - [Tarter USA Announces Acquisition of Vail Products](https://longbridge.com/en/news/286956990.md)